Syner-G is excited to participate in CDMO Live Americas 2026, the award-winning event where biopharma leaders connect with development and manufacturing partners, exchange insights, and build more resilient outsourcing strategies.
Designed to facilitate meaningful conversations and strategic partnerships, CDMO Live brings together the outsourcing community to address the challenges and opportunities shaping the future of drug development and manufacturing.
Featured Panel
CMC Strategy for Funding Success: What Investors Evaluate at Each Stage—and How to Demonstrate Readiness
October 21, 2026 | 11:40 AM
Join Ray Forslund, PhD, MBA, EVP of Product Development at Syner-G, as he shares insights on the critical role CMC strategy plays in securing investment and advancing development programs.
This panel will explore how investors assess CMC readiness from Seed through IPO, the key elements of an investment-ready development plan, and practical approaches for demonstrating development progress, manufacturability, and risk mitigation without overinvesting before funding is secured.
Whether you’re preparing for your next financing round, selecting development and manufacturing partners, or advancing a therapeutic program toward commercialization, we’d welcome the opportunity to connect.
Meet with Ray and the Syner-G team to discuss strategies for building value through CMC excellence.
About Ray
Ray brings over 20 years of experience at the intersection of pharmaceutical science and business leadership, with a career defined by building high-performing teams and translating complex scientific programs into commercial results. At Syner-G, he leads a team of 60+ professionals spanning CMC development, regulatory CMC, quality, supply chain and project management delivering end-to-end solutions for biotech and pharmaceutical clients across biologics, small molecules, and peptides.
Ray has built a reputation for getting programs done right helping emerging biotechs, CDMOs, and established pharmaceutical companies navigate the full development continuum from early-stage IND through late-phase and commercialization. Clients turn to Ray and his team when the science is complex, the timelines are tight, and the stakes are high. His ability to combine deep technical expertise with sharp operational execution means programs move forward with fewer surprises and greater confidence. Whether standing up a CDMO partnership, resolving a development bottleneck, or building out a client’s internal capabilities, Ray brings the scientific credibility and strategic clarity that teams need to make critical decisions and deliver results.
Ray holds a Ph.D. in Organic Chemistry from the University of Illinois at Chicago and an MBA from Babson College.
